Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Business22 hours agoWhy did Pilbara Minerals shares rocket 50%+ in August?
-
General22 hours agoJournalist seeks big penalty after illegal ABC sacking
-
General21 hours ago“Shag on a Rock”. India’s embrace of China highlights Australia’s quandary
-
Noosa News20 hours agoLNP, Greens call for name changes and scrapped seats as Queensland electoral boundaries reviewed